FDA endorsement moves once-weekly sutacimig into decisive Glanzmann thrombasthenia study
Sutacimig gets an FDA-backed Phase 3 path after sustained bleed reductions in Glanzmann thrombasthenia. Read what the pivotal trial must prove.
Pharma & Biotech
Pharma & Biotech
Can Hemab Therapeutics’ sutacimig finally deliver the first preventive therapy for Glanzmann thrombasthenia after FDA breakthrough designation?
FDA grants Breakthrough Therapy Designation to Hemab Therapeutics’ sutacimig for Glanzmann thrombasthenia. Discover what this means for bleeding disorder treatment.